We suggest that this may result to some extent in an “exhaustion phenotype,” i.e., expression of inhibitory checkpoint receptors that will respond toward TIGIT-blockade when tested against CD155+-AML cell lines. This evidence concerns the gene PVR and acute myeloid leukemia.